DJIA 18,126.12 -36.87 -0.20%
NASDAQ 5,097.98 -8.62 -0.17%
S&P 500 2,120.79 -2.69 -0.13%
market minute promo

9.34 -0.02 (-0.21%)

REAL-TIME: Last trade at


company name or ticker

Recent Quotes

ACHN $9.34 -0.21%
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $9.36
Previous Close $9.36
Daily Range $9.09 - $9.37
52-Week Range $2.65 - $16.87
Market Cap $1.1B
P/E Ratio -13.37
Dividend (Yield) $0.00 (0.0%)
Volume 2,546,324
Average Daily Volume 3,807,251
Current FY EPS -$0.78

Sector

Healthcare

Industry

Drug Makers

ACHILLION PHARMACEUTICALS, INC. (ACHN) Description

A biopharmaceutical company focuses on the discovery, development and commercialization of innovative treatments for infectious diseases Website: http://www.achillion.com/

News & Commentary

Gilead's Sustainable Competitive Advantage

Gilead Sciences' long-term growth is being doubted by the Street because of the uncertainty surrounding the hep C market going forward. The biotech's top notch CEO John Martin, however, should be reason enough for investors to believe that company's best days lie ahead. Here's why.

The Janssen-Achillion Deal Proves My Short Thesis

Seeking Alpha's Biotech Weekly: J&J-Achillion Vs. Gilead, MannKind's Marketing, And More

J&J (JNJ) to File for More than 10 New Products by 2019 - Analyst Blog

UBS and JMP Securities Downgrade Achillion Pharmaceuticals Inc. ...

Johnson & Johnson Just Stepped Up Its Hepatitis C Game

Johnson & Johnson has inked a licensing deal with Achillion Pharmaceuticals that could threaten Gilead Sciences market share in hepatitis C. Should Gilead investors worry?

The Zacks Analyst Blog Highlights: Eleven Biotherapeutics, bluebird, Agios, Acceleron and Achillion

The Zacks Analyst Blog Highlights: Eleven Biotherapeutics, bluebird, Agios, Acceleron and Achillion - Press Releases

Gilead, Merck And Achillion/J&J Square Off In An HCV 'Nuc'lear Showdown

What Does The Johnson & Johnson/Achillion Deal Mean For HCV Competitors?

Biotech Stock Roundup: Eleven Bio Slumps on Eye Drug Data, Achillion Signs Deal with J&J - Analyst B

Biotech Stock Roundup: Eleven Bio Slumps on Eye Drug Data, Achillion Signs Deal with J&J - Analyst Blog

See More ACHN News...

ACHN's Top Competitors

ACHN $9.34 (-0.21%)
Current stock: ACHN
AMGN $157.35 (-1.93%)
Current stock: AMGN
GILD $112.85 (0.35%)
Current stock: GILD
BIIB $400.10 (-0.70%)
Current stock: BIIB